Browse by author
Lookup NU author(s): Dr Rhys ThomasORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature. Valproate is a broad-spectrum antiepileptic drug (AED) of particular interest in pediatric epilepsy syndromes and idiopathic generalized epilepsy, as it is relatively more effective in these syndromes than other AEDs. In 2018, the European Medicines Agency introduced new restrictions on the use of valproate in girls and women of childbearing potential to avoid exposure during pregnancy. The strengthening of existing restrictions sparked controversy and debate among patients and the medical community. The high prevalence of epilepsy syndromes amenable to valproate treatment in women of childbearing age and the little information available on the teratogenic potential of alternative treatments have created uncertainty on how to manage these patients. In this consensus statement, based on a review of the literature and the clinical experience of a panel of European epilepsy experts, we present general recommendations for the optimal clinical management of AED treatment in girls, women of childbearing potential, and pregnant women across the different epilepsy syndromes.
Author(s): Toledo M, Mostacci B, Bosak M, Jedrzejzak J, Thomas RH, Salas-Puig J, Biraben A, Schmitz B
Publication type: Review
Publication status: Published
Journal: Journal of Neurology
Print publication date: 01/08/2021
Online publication date: 01/04/2020
Acceptance date: 24/03/2020
ISSN (print): 0340-5354
ISSN (electronic): 1432-1459
PubMed id: 32239268